The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.
According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample
Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline
In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.
OX-40 Receptor Agonist Therapeutics Pipeline Analysis
· By Phase
· By Molecule Type
· By Route of Administration
· By Company
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
No comments:
Post a Comment